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a b s t r a c t
It is extremely rare for metastasised medulloblastoma to form a large tumour in the
suprasellar region. We present a case of medulloblastoma with large suprasellar metastasis
at initial presentation. A 3-year and 5-month-old boy presented with a 1-month history of
vomiting and loss of appetite, and body weight. Computed tomography and magnetic
resonance imaging revealed a 20 mm  20 mm mass in the suprasellar region and a
30 mm  30 mm mass in the fourth cerebral ventricle. We performed endoscopic biopsy
of the suprasellar tumour, and subsequently totally removed the vermian tumour through a
suboccipital craniotomy. The histopathological ﬁndings revealed that both the suprasellar
and vermian tumours were classic type and non SHH/WNT type medulloblastoma. The
postoperative course was uneventful. The patient showed complete remission after
chemotherapy. The tumour in the suprasellar region was most likely metastatic from the
vermis. Endoscopic biopsy of the tumour in the suprasellar region and total removal of
the tumour in the vermis in a one-stage operation followed by intensive chemotherapy with
reduced dose radiotherapy may provide a satisfactory outcome.
# 2016 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Medulloblastoma is the most common paediatric brain
tumour with invasive and metastatic potential. The presence
of metastatic disease in patients newly diagnosed with* Corresponding author at: Department of Neurosurgery, Kobe Univers
650-0017 Kobe, Japan. Tel.: +81 78 382 5966; fax: +81 78 382 5979.
E-mail address: hn0628hn@med.kobe-u.ac.jp (H. Nagashima).
http://dx.doi.org/10.1016/j.pjnns.2016.02.001
0028-3843/# 2016 Polish Neurological Society. Published by Elsevier Smedulloblastoma remains one of the most important prog-
nostic factors [1]. Although leptomeningeal metastasis of
medulloblastoma is frequent, suprasellar metastasis is un-
common [2–6]. We report here an extremely rare case of
medulloblastoma that formed tumours of similar size in the
suprasellar region and vermis.ity Graduate School of Medicine, 7-5-2, Kusunoki cho, Chuo-ku,
p. z o.o. All rights reserved.
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2.1. History and examination
A 3-year and 5-month-old boy presented with a 1-month
history of vomiting and loss of appetite and body weight. The
patient was originally healthy and had no developmental
abnormalities. His only medical history was of bronchial
asthma. Although headache and vomiting were observed, no
other neurological abnormalities were evident on admission.
Laboratory studies showed negative serum tumour markers,
and endocrinological examination detected incomplete hypo-
pituitarism. The posterior pituitary function was preserved.
Thyroid hormone was replaced preoperatively. Ophthalmo-
logical examination showed no optic atrophy or papilloedema.
2.2. Imaging ﬁndings
Two tumours in the suprasellar region and cerebellar vermis
were evident on screening computed tomography (CT). CranialFig. 1 – Preoperative images. Preoperative axial computed tomo
vermis, with mild hydrocephalus (Left). Homogeneous enhance
dissemination (Right).
Fig. 2 – Sagittal magnetic resonance T1-weighted images obtaine
hypointensity in tumours in the suprasellar region and vermis (
following chemotherapy and radiation therapy, showing resolutCT revealed a 20 mm  20 mm mass in the suprasellar region
and a 30 mm  30 mm mass in the fourth cerebral ventricle
with mild ventricular enlargement. Small punctate calciﬁca-
tions were noted in the tumours. Enhanced CT showed
homogeneous enhancement of the tumours without sub-
arachnoid or intraventricular metastatic lesions (Fig. 1).
Cranial magnetic resonance imaging (MRI) showed isointense
tumours on T1 weighted, T2 weighted, and FLAIR images in
both the suprasellar region and fourth cerebral ventricle. The
size of the suprasellar tumour was 20 mm  20 mm  32 mm
and the size of vermian tumour was 30 mm  30 mm  35 mm
(Fig. 2a). Because the patient experienced an asthma attack
during contrast-enhanced CT, gadolinium-enhanced MRI was
not performed. No clear dissemination was apparent on the
FLAIR image of either cranial or spinal MRI.
2.3. Operation and postoperative course
Endoscopic biopsy was performed on the suprasellar tumour
and an indwelling ventricular drain was placed. Intraoperative
pathological diagnosis of this tumour was not germinoma butgraphy scan showing tumours in the suprasellar mass and
ment on contrast-enhanced images without evidence of
d at the initial presentation. Arrows indicate homogeneous
a). Image after removal of the tumour in the vermis (b) and
ion of the tumour in the suprasellar region (c).
Fig. 3 – Photomicrographs of the tumours in the suprasellar region (Left) and vermis (Right). Similar histopathological features
of classic medulloblastoma in each of highly dense oval shaped cells having a high N/C ratio, karyokinesis, and karyorrhexis.
H&E, original magnify, both 100T.
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neuroectodermal tumour (PNET). The patient was then placed
in the prone position and the vermian tumour was totally
removed through a suboccipital craniotomy; the intraoperative
pathological diagnosis was also medulloblastoma. Cerebrospi-
nal ﬂuid (CSF) cytology from the third ventricle was negative.
The postoperative course was uneventful and the extra-
ventricular drain was removed on postoperative day 3. MRI
showed no residual tumour in the vermis (Fig. 2b) and CSF
cytology was negative for malignant cells.
2.4. Pathological ﬁndings
Histological ﬁndings conﬁrmed a diagnosis of medulloblasto-
ma, classic type (Fig. 3). A diffuse proliferation of oval blue cells
with a high nuclear cytoplasmic (N/C) ratio, karyokinesis, and
karyorrhexis were observed. Similar images were obtained for
the suprasellar region and vermis. The immunostaining
results for both tumours were BAF47 (+++), synaptophysin
(+++), neuroﬁlament (+++), GFAP (+++), S-100 (), and a MIB1
index of 41.6%. The pathological diagnosis was embryonal
tumour, WHO grade 4, classic medulloblastoma of the fourth
ventricle or CNS PNET of the suprasellar region. The b-Catenin
(), Dickkopf-1 (DKK-1) (), Yes-associated protein (YAP) (),
Secreted frizzled-related protein-1 (SFRP-1) (), c-MYC (). The
ﬁnding suggest that the tumour was non sonic hedgehog
(SHH)/wingress (WNT) type medulloblastoma.
2.5. Chemotherapy and radiation therapy
Chemotherapy was started at 21 postoperative days as stated
in the protocol of the Japanese Pediatric Brain Tumor
Consortium. Assuming this was a case of suprasellar
metastasis from the primary vermian medulloblastoma, we
categorised the case as high-risk based on the postoperative
disease stage classiﬁcation for medulloblastoma. After four
chemotherapy courses (cyclophosphamide, cisplatin, vincris-
tine, and etoposide), high-dose chemotherapy (thiotepa and
melphalan) was performed together with autologous periph-
eral blood haematopoietic stem cell transplantation as salvage
therapy. The patient received reduced-dose craniospinal
irradiation (18 Gy) with a boost to the tumour bed (total dose,
50 Gy). The suprasellar tumour had regressed to achievecomplete remission during the ﬁrst course of chemotherapy.
Cranial and spinal MRI after completion of chemo-radiation
therapy showed complete remission (Fig. 2c). No recurrence
or neurological deﬁcit has been evident as of 3 years after
the operation.
3. Discussion
3.1. Clinical features
Medulloblastoma is the most common malignant brain
tumour in childhood and has invasive and metastatic
properties. These tumours account for 15–20% of all paediat-
ric central nervous system neoplasms [7]. Medulloblastoma
mostly occurs in boys aged 3–9 years and approximately
10–15% of cases are diagnosed in infancy [1]. The tumour
occurs mainly in the cerebellar vermis and tends to invade
the fourth ventricle and cerebellar hemispheres. The pres-
ence or absence of metastasis is important for postoperative
treatment. Metastasis of medulloblastoma is common, and
it is believed that seeding occurs mainly in the spinal
subarachnoid space, basal cistern, Sylvian ﬁssure, and in
any subependymal lesions of the lateral ventricle or any
subfrontal lesions [7]. Although several cases of medulloblas-
toma metastasising to the suprasellar region have been
reported, the formation of a single large tumour at initial
diagnosis has been rarely reported.
Metastasis to the suprasellar region has been documented
in recurrent medulloblastoma, but bulky metastatic disease at
presentation is rare [2–6]. Helton et al. reviewed 130 children
with medulloblastoma and reported 6 cases (4.6%) of medul-
loblastoma metastatic to the anterior third ventricular recess
at diagnosis [5]. The suprasellar metastases ranged in size
from 4 to 11 mm. Fukusumi et al. reported 2 cases with a
nodular metastatic focus in the suprasellar region [3]. Both
cases were clinically occult and the tumours were smaller than
in the present case. Shelton et al. presented a 32-year-old man
with classic medulloblastoma that showed intraventricular
spread via subarachnoid dissemination of the disease from the
fourth ventricle to the suprachiasmatic recess of the third
ventricle [6]. In addition, Lee et al. reported 3 cases of recurrent
medulloblastoma within the fourth ventricle and a large
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diameter) with accompanying ependymal metastasis [8].
Gupta et al. reported an adult case of medulloblastoma with
a large suprasellar mass in which the pathological diagnosis
was classic medulloblastoma and CSF cytology was negative,
as in our case [4]. To our knowledge, the present case is the ﬁrst
involving such a large metastatic medulloblastoma (approxi-
mately 20 mm) in the suprasellar region.
It is possible that our case represents vermian metastasis of
a suprasellar PNET. PNETs typically occur in the cerebral
hemisphere or lateral ventricle [9] and less typically in the
suprasellar region. In addition, there have been no reports of
vermian metastasis of suprasellar PNETs to date. Accordingly,
in our case, metastasis of a suprasellar PNET to the vermis
would be a less likely diagnosis. There is also the possibility
that our case is a supratentorial PNET with a synchronous
medulloblastoma. Multifocal medulloblastoma has previously
been reported in 4 adult cases, all of which involved
infratentorial lesions that were classic medulloblastoma
histologically [10–13]. There have been no reports of cases in
which medulloblastoma occurred in both the suprasellar
region and vermis simultaneously. Therefore, in our case,
simultaneous onset of PNET in the suprasellar region and
medulloblastoma in the vermis would also be a less likely
diagnosis. When cerebellar and suprasellar region tumours
co-exist, even if there are no ﬁndings of metastasis on MRI or
cerebrospinal ﬂuid analysis, we should consider metastasis.
3.2. Treatment and outcome
Medulloblastoma is commonly treated with surgery, chemo-
therapy, and radiotherapy and the course decided depends on
patient age, size of the residual tumour, and the presence or
absence of dissemination [1,14]. There is no standard approach
to treatment for tumours occurring simultaneously in the
supratentorial and infratentorial regions [4–6]. In the present
case, the tumours were considered to be malignant, so the
operative approach was designed to enable chemotherapy to
be started as early as possible. Endoscopic biopsy of the
suprasellar tumour would provide a histological diagnosis
without further hypothalamo-pituitary dysfunction caused by
tumour removal; simultaneous endoscopic third ventriculost-
omy was impossible due to the presence of the massive third
ventricle tumour; and total removal of the fourth ventricular
tumour would provide a histological diagnosis and enable CSF
circulation to be reestablished to avoid a shunt operation.
In this rare case of medulloblastoma with tumours of similar
size in both the suprasellar region and vermis, the radiographic
variation may be clinically relevant when considering the
differential diagnosis from preoperative images. In similar
cases, endoscopic biopsy of the tumour in the suprasellar region
and total removal of the tumour in the vermis in a one-stage
operation followed by intensive chemotherapy with reduced-
dose radiotherapy may provide a satisfactory outcome.
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